Global Esophageal Cancer Market Analysis 2024, Forecast To 2033
8 Mar, 2024
The esophageal cancer market size has surged, from $1.25 billion in 2023 to $1.38 billion in 2024, with a 10.0% CAGR. Historic growth stems from increased cancer cases, healthcare enhancements, and lifestyle factors like alcohol consumption. Future growth to $1.94 billion by 2028, at 8.9% CAGR, is driven by rising cancer prevalence, healthcare improvements, and lifestyle choices. Anticipated trends include treatment advancements, research investments, and collaborations.
Global Esophageal Cancer Market Key Driver
The esophageal cancer market is growing in response to the increasing incidence of esophageal cancer. By 2040, the incidence rate of esophageal adenocarcinoma is projected to rise by 82%, highlighting the need for diagnostic procedures and treatment options.
Get A Free Sample Of The Global Esophageal Cancer Market ReportGlobal Esophageal Cancer Market Segments
The esophageal cancer market covered in this report is segmented –
1) Type:Esophageal Squamous-Cell Carcinoma, Esophageal Adenocarcinoma, Other Types
2) Treatment Type:Chemotherapy, Targeted Therapy, Other Treatment Types
3) Route Of Administration:Oral, Parenteral, Other Routes Of Administration
4) Distribution Channel:Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) End Users:Hospitals, Homecare, Specialty Centers, Other End Users
By Geography: The countries covered in the esophageal cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
North America was the largest region in the esophageal cancer market in 2023. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the esophageal cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Esophageal Cancer Industry Players
Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc; AbbVie Inc.; Bayer AG; Novartis AG; Sanofi S.A; Bristol-Myers Squibb Company; AstraZeneca PLC; GlaxoSmithKline Plc.; Takeda Pharmaceutical Company Limited; Eli Lilly and Co Ltd.; Boehringer Ingelheim International GmbH; Gilead Sciences Inc.; Amgen Inc.; Teva Pharmaceutical Industries Ltd.; Astellas Pharma Inc.; Daiichi Sankyo Company Limited; Servier Pharmaceuticals; Eisai Co. Ltd.; Sun Pharmaceutical Industries Limited; Otsuka Pharmaceutical Co. Ltd.; Ipsen SA; Dr. Reddy's Laboratories Ltd.; Seagen Inc.; Exelixis Inc.; BeiGene Ltd.; Clovis Oncology Inc.; Aslan Pharmaceuticals Ltd.
Get The Full Global Esophageal Cancer Market Report
Esophageal Cancer Market Overview
Esophageal cancer refers to a type of cancer that arises in the cells lining the esophagus, the muscular tube that carries food and drinks from the neck to the stomach. This occurs when abnormal cells in the food pipe (esophagus) develop uncontrollably and cause cancer.